Content authored by practitioners with experience at Amazon India, Intuit QuickBooks, and the Tata Group. Meet the team →
Indian pharma companies claim Section 35(2AB) deduction on in-house R&D — historically a 150% weighted deduction, sunset to 100% from FY 2020-21 onward — and must reconcile every rupee of claimed spend against DSIR Form 3CK recognition, audited Form 3CLA filing, and Form 3CL quantification, with strict carve-outs for land, building, marketed-product clinical trials, and out-of-facility research. Variance between the company's claim and DSIR's quantification typically runs 8-15%, and the assessing officer accepts only the Form 3CL number at scrutiny.
Reconcile R&D cost-centre GL lines into four buckets (eligible capex, eligible revenue, ineligible-carve-out, out-of-scope), tie every fixed-asset addition to the R&D facility registration number, match every vendor invoice to a work-completion certificate from the recognised facility head, file Form 3CLA with the statutory auditor's certificate by 31 October, and book the income-tax return claim equal to the Form 3CL quantified number — not the company's own claim. Withholding on R&D vendor payments runs in parallel under Section 393/395 payment codes, separate from the 35(2AB) computation.
DSIR registration number on the R&D facility master, R&D cost-centre taxonomy with eligibility flag per centre, vendor master tagged for CRO vs scientific-consultancy vs equipment-AMC with the matching TDS code, fixed-asset register filter for R&D scientific equipment with land/building exclusion, Form 3CLA worksheet template (capex schedule + revenue schedule + auditor sign-off section), Form 3CL variance log per assessment year, cross-era legacy-section cross-reference for pre-FY26 transactions, TDS code map (1002 contractor, 1003 professional, 1052 non-resident).
An annual Form 3CLA-ready schedule showing eligible capex by asset class with FAR linkage, eligible revenue spend by cost centre with vendor-invoice and work-completion-certificate references, ineligible spend logged for transparency, Form 3CL variance closed within the year, monthly TDS challan on R&D vendor payments under codes 1002/1003/1052 reconciled to 26AS, and a cross-era cross-reference report tying pre-FY26 legacy-section transactions to the new payment-code regime.
A mid-cap Indian pharmaceutical formulator with two recognised R&D facilities — one in Hyderabad, one in Ahmedabad — closes FY26 and tallies its R&D spend: ₹68 crore across the two facilities. The CFO files Form 3CLA on 31 October with ₹68 crore as claimed eligible expenditure. DSIR returns Form 3CL three months later quantifying ₹61.4 crore — a ₹6.6 crore (9.7%) disallowance. The income-tax return must be filed at ₹61.4 crore, not ₹68 crore. The ₹6.6 crore variance is the cost of weak reconciliation between the books and the four-bucket eligibility taxonomy. This is the operating reality of pharma R&D Section 35(2AB) India compliance — the section is live, the cycle is annual, and the reconciliation discipline is where money leaks.
Quick reference
| Item | Value |
|---|---|
| Statutory anchor | Section 35(2AB), Income Tax Act |
| Historical rate | 150% weighted deduction (up to FY 2019-20 / AY 2020-21) |
| Current rate | 100% deduction (FY 2020-21 onward — weighted uplift sunset) |
| Recognition body | DSIR (Department of Scientific and Industrial Research) |
| Recognition form | Form 3CK (application), renewed every three years |
| Annual return | Form 3CLA — audited eligible expenditure, due 31 October |
| Quantification | Form 3CL — DSIR’s accepted amount, binding on the assessee |
| Eligible | In-house R&D capex (excl. land/building), revenue spend at the recognised facility |
| Ineligible | Land, building, marketed-product clinical trials (Phase IV), out-of-facility research |
| Typical DSIR disallowance | 8% to 15% of claimed amount |
| Cross-era treatment | Section 35(2AB) reference preserved under Income Tax Act 2025 computation |
What is Section 35(2AB) and how did the weighted deduction sunset?
Section 35(2AB) of the Income Tax Act allowed a weighted deduction — initially 200%, reduced to 150% from AY 2018-19, then to 100% from AY 2021-22 — on in-house R&D expenditure incurred at a facility recognised by DSIR. The provision was designed to subsidise indigenous R&D investment in pharmaceuticals, biotech, drugs, electronics, automotive, aerospace and a defined list of priority sectors. The sunset of the weighted component was part of the broader move under the Taxation Laws (Amendment) Act 2019 to reduce statutory rates while withdrawing sector-specific incentives.
The section remains operationally important after the sunset for three reasons. First, the 100% deduction still requires DSIR recognition and Form 3CL quantification — without those, the spend reverts to ordinary Section 37(1) treatment with no guarantee of full allowance. Second, DSIR-recognised status is a prerequisite for several state R&D incentives — Karnataka’s R&D Policy, Telangana’s Life Sciences Policy and Gujarat’s R&D Capital Subsidy all key off DSIR recognition. Third, the discipline of the 35(2AB) audit cycle — segregating eligible from ineligible spend, evidencing facility-level work — is what gives the income-tax return claim credibility at scrutiny.
How does DSIR recognition work — Form 3CK, 3CLA, 3CL?
The three-form chain runs on a fixed annual cycle.
Form 3CK — facility recognition. The company applies to DSIR to recognise a specific in-house R&D facility, providing the facility address, the names and qualifications of R&D scientists, a description of the research programme, expected investment, and the company’s own R&D policy document. DSIR conducts a site visit before granting recognition. The recognition certificate carries a registration number and is valid for three years, after which renewal is filed. A company can hold multiple facility recognitions — typical Indian pharma majors hold three to seven separate DSIR registrations across formulations, APIs, biologics and biosimilars R&D.
Form 3CLA — annual eligible-expenditure return. Due 31 October of the assessment year (i.e., for FY26 ending March 2026, due 31 October 2026). Contains audited eligible R&D expenditure for the financial year, split between capital and revenue, signed by the statutory auditor under a 35(2AB)-specific audit certificate. The capex schedule lists each scientific equipment addition with FAR reference, asset class, and value; the revenue schedule lists salaries of R&D scientists, consumables, utilities, depreciation on R&D equipment, patent costs, and pre-clinical work.
Form 3CL — DSIR quantification. Issued by DSIR after reviewing the 3CLA, typically three to six months after filing. States the amount DSIR has accepted as eligible under Section 35(2AB). The income-tax return claim must equal the Form 3CL number — any excess is disallowed at scrutiny. Where 3CL is delayed beyond the income-tax return filing date, the company files at the 3CLA claimed amount and revises if 3CL quantifies lower.
What expenses are eligible and what is carved out?
The eligibility line in Section 35(2AB) is narrow and binding.
Eligible — capital:
- Scientific research equipment installed at the recognised facility (HPLC, mass spectrometers, dissolution apparatus, bioreactors, lyophilisers)
- R&D-specific computer hardware and laboratory information management systems (LIMS)
- Patent filing and prosecution costs capitalised under accounting policy
- Process development equipment for new molecule scale-up
Eligible — revenue:
- Salaries of scientists and technicians on the recognised facility’s payroll
- Consumables — reagents, solvents, reference standards, API samples
- Utilities apportioned to the R&D block (electricity, water, gas, HVAC)
- Depreciation on R&D scientific equipment
- Patent maintenance fees expensed
- Pre-clinical studies (in-vitro, in-vivo on new molecules)
- Early-phase clinical trials (Phase I, II, III) on new molecules pre-marketing approval
Ineligible (carved out from 35(2AB)) but allowable elsewhere:
- Land — never eligible
- Building — separately allowable under Section 35(1)(iv) at 100% capex, but excluded from 35(2AB)
- Phase IV / post-marketing clinical trials on a product that already has marketing approval — treated as marketing spend, not R&D
- Research outsourced to a third-party CRO unless conducted at the recognised facility under the company’s direct supervision
- MR salaries, distribution costs, brand-promotion spend — out-of-scope entirely
Common DSIR disallowance reasons in the Form 3CL letter:
| Disallowance reason | Typical % of total disallowance |
|---|---|
| Phase IV / marketed-product trial spend mistakenly claimed | 25% to 40% |
| Salaries of staff not exclusively on R&D facility payroll | 15% to 25% |
| Out-of-facility consumables and equipment | 10% to 20% |
| Building maintenance costs included in revenue | 5% to 15% |
| CRO outsourcing without supervision evidence | 10% to 20% |
Worked example — ₹68 Cr annual R&D spend
A mid-cap formulator with Hyderabad and Ahmedabad R&D facilities, both DSIR-recognised, ₹68 crore total R&D spend for FY26.
Initial claim composition (Form 3CLA, filed 31 October 2026):
| Bucket | Amount |
|---|---|
| Eligible capex (scientific equipment, LIMS, patent capex) | 18.0 Cr |
| Eligible revenue — R&D scientist salaries | 22.5 Cr |
| Eligible revenue — consumables, reagents, reference standards | 9.8 Cr |
| Eligible revenue — utilities apportioned to R&D block | 3.2 Cr |
| Eligible revenue — depreciation on R&D equipment | 6.5 Cr |
| Eligible revenue — pre-clinical and Phase I-III on new molecules | 5.0 Cr |
| Other (patent maintenance, lab software, AMC) | 3.0 Cr |
| Total Form 3CLA claim | 68.0 Cr |
Form 3CL quantification (received January 2027):
| Disallowance | Amount |
|---|---|
| Phase IV trial on existing brand mistakenly classified as new-molecule trial | 2.4 Cr |
| Salaries of three staff with split R&D-and-regulatory affairs roles | 1.6 Cr |
| Building HVAC maintenance booked as utility apportionment | 0.9 Cr |
| CRO outsourcing without facility-head countersignature on work-completion | 1.2 Cr |
| Reagents shipped to a non-recognised pilot facility | 0.5 Cr |
| Total DSIR disallowance | 6.6 Cr |
| Form 3CL quantified amount | 61.4 Cr |
The income-tax return claim is filed at ₹61.4 crore. The ₹6.6 crore disallowance is reversed in the computation. A reconciliation memo logs each disallowance reason and feeds the next year’s pre-filing taxonomy review so the same items do not recur.
Three-way match every CRO invoice to work-completion certificate and facility code
Every CRO and consultancy invoice must tie to a work-completion sign-off from the recognised R&D facility head, with the facility registration number on the document, before it counts as eligible 35(2AB) spend. The three-way match exception cost calculator shows the cash exposure when this discipline slips.
Open the calculator →Tax overlay — withholding on R&D vendor payments
Section 35(2AB) sits in computation of income. The withholding regime — Chapter XVII of the Income Tax Act 2025 — runs separately on every R&D vendor payment, and the codes are the new payment-code map (1001-1092) that replaced the legacy 194-series sections from 1 April 2026.
Section 393, code 1002 — contractor TDS on CRO contracts, equipment AMC, calibration, lab maintenance services. Rate 1% (individual/HUF), 2% (company/firm); threshold ₹30,000 per transaction, ₹1 lakh aggregate per annum. Replaces legacy Section 194C.
Section 393, code 1003 — professional and technical fees TDS on scientific consultancy by individual scientists, lab software classified as technical service, patent attorney fees. Rate 10%; threshold ₹30,000 aggregate per annum. Replaces legacy Section 194J.
Section 395, code 1052 — non-resident payments on imported research chemicals, foreign CRO contracts, overseas scientific consultancy. Rate per treaty (usually 10% on royalty/FTS); requires Form 15CA/15CB and the DTAA benefit certificate. Replaces legacy Section 195.
Cross-era note. Invoices booked before 1 April 2026 carry legacy section references (194C for code 1002, 194J for code 1003, 195 for code 1052) and the corresponding Form 26AS data continues to show legacy section labels. Reconciliation against historical 26AS must keep the legacy-to-new cross-reference live for at least one full tax-year cycle — see TDS payment codes 1001-1092 India and Section 393 TDS new Income Tax Act reconciliation for the full mapping.
Section 35(2AB) treatment in the Income Tax Act 2025. The 2025 Act preserves Section 35(2AB) numbering and substantive treatment — the 100% deduction continues, DSIR recognition continues, Form 3CL quantification remains binding. The provision is now placed within the rewritten Chapter IV-D (computation of business income) of the 2025 Act with the original 35(2AB) section reference retained for continuity of case law and DSIR procedural references.
Reconciliation against books — the three discipline rails
A defensible Section 35(2AB) claim closes three reconciliations every year before the auditor signs Form 3CLA.
Rail 1 — GL reconciliation. Every R&D cost-centre GL line is mapped at trial-balance level to one of four buckets: eligible capex, eligible revenue, ineligible-carve-out, out-of-scope. The mapping is documented at vendor-master and cost-centre-master level so the statutory auditor can re-perform the segregation without re-judging individual transactions. Mid-year drift — a new vendor added without a TDS-and-eligibility flag, a cost centre renamed without the eligibility taxonomy carrying through — is where most disallowances originate.
Rail 2 — Fixed-asset register reconciliation. Every R&D scientific equipment addition during the year is tied to: the purchase invoice, the cost-centre code, the asset class (eligible R&D capex), the FAR addition reference, the installation site (must match the DSIR-recognised facility address), and the depreciation booked. Equipment installed at a pilot facility that is not yet DSIR-recognised is ineligible until recognition extends to that site.
Rail 3 — Vendor-payment reconciliation. Every CRO and scientific consultancy payment is matched to a work-completion certificate signed by the recognised R&D facility head, confirming the work was performed at the approved facility. The certificate carries the facility registration number and the engagement reference. Without the certificate the payment is recharacterised as outsourced research and disallowed under 35(2AB). The parallel TDS reconciliation ties the deduction at source (codes 1002/1003/1052) to Form 26AS and to the vendor’s PAN — a separate computation from the 35(2AB) eligibility but required for the underlying expense to be allowable at all.
For the related pharma reconciliation work on inverted-duty GST refunds — which use the same vendor-master and cost-centre discipline — see pharma GST refund under inverted duty structure (Rule 89(5)).
What automated reconciliation changes
Manual 35(2AB) reconciliation across the three rails plus the TDS overlay is a 12-15 day exercise at a mid-cap pharma R&D-led close, and the 8-15% DSIR disallowance band rarely closes below 6% without dedicated tooling. Purpose-built reconciliation software India treats the four-bucket eligibility taxonomy as a structured variance stream, ties each vendor invoice to its work-completion certificate, and surfaces only the lines that fail the facility-registration or eligibility check. TransactIG carries 24+ industry presets, including a pharma R&D configuration that handles DSIR facility-master tracking, Form 3CLA worksheet generation from cost-centre data, Form 3CL variance logging by assessment year, and the Section 393/395 deduction map on R&D vendor payments. Customer outcomes include match-rate improvement from 51% to 88% on the underlying AP and AR streams, and exception rates in the sub-15% band post-implementation. Build is two-to-four weeks on AWS Mumbai (ISO 27001:2022). For the GST side of the pharma close — credit-note reconciliation, GSTR-2B matching on R&D consumables, inverted-duty refund — see GST reconciliation software.
DSIR — the recognising authority
DSIR (Department of Scientific and Industrial Research, under the Ministry of Science and Technology) administers Form 3CK recognition, the annual Form 3CLA review, and the Form 3CL quantification protocol. For the current scheme guidelines, application formats, and the list of currently recognised in-house R&D facilities see the Department of Scientific and Industrial Research (DSIR). Pharma companies typically maintain a year-round liaison with DSIR’s R&D unit because facility renewals, address changes, programme expansions and scientist on-boarding all require DSIR notification within fixed windows.
Continue reading the pharma cluster
- Pharma distributor and stockist reconciliation in India — the downstream channel rail
- Pharma GST refund under inverted duty structure (Rule 89(5)) — formulation-grade GST refund mechanics
- Medical representative (MR) settlement reconciliation — field-force expense and incentive settlement